Back HIV Disease Progression

HIV Disease Progression

ICAAC 2012: People with Low-level Viral Load Are at Risk for Treatment Failure and Poor CD4 Recovery

Individuals who still have low levels of plasma HIV RNA despite taking antiretroviral therapy (ART) may experience treatment failure, and those with HIV residual DNA in their T-cells may not achieve expected CD4 cell gains, according to 2 studies presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco. alt

Read more:

AIDS 2012: More People Starting HIV Treatment, Lower Viral Load in NA-ACCORD Study

More than 80% of HIV patients in the large North American ACCORD study are receiving combination antiretroviral therapy (ART), about 70% have suppressed viral load -- up from less than 50% in 2000 -- and the median age at the time of death rose by 6 years, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.


Read more:

AIDS 2012: Incomplete CD4 T-Cell Response to ART Raises Mortality Risk

Having fewer than 700 CD4 cells/mm3 and hepatitis C coinfection were associated with greater risk of death in a study of U.S. veterans, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC, suggesting that it may be beneficial to start antiretroviral treatment before CD4 counts fall to this level. alt

Read more:

Lack of Food Linked to More Hospitalizations among HIV+ People with Unstable Housing

Homeless and marginally housed people with HIV in San Francisco who experienced "food insecurity" -- lack of stable access to sufficient nutrition -- were more likely to visit the emergency department and more likely to be hospitalized than people with a steady source of adequate food, researchers reported in the August 18, 2012, advance online edition of the Journal of General Internal Medicine. alt

Read more:

CROI 2012: Infants with HIV Who Receive Early ART Can Safely Stop Treatment

HIV-infected infants who start antiretroviral therapy (ART) immediately after birth can interrupt treatment after 1-2 years and still do better than babies who delayed ART initiation until they developed symptoms, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this month in Seattle.alt

Read more: